Bryhali (Halobetasol Propionate) Patent Expiration, LOE Window & CMS Spending

Bryhali (Halobetasol Propionate) by Bausch Health: FDA Orange Book LOE 2031-11-02, 7 AB generics, $154K 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN209355 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-11-02
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$154K
2024 Medicare Part D Spend$101K
2024 Medicaid Spend$53K
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 22.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.